Doctors Prescribe Unapproved Weight-Loss Drug Retatrutide Amid Safety Concerns

1-Minute Brief

The off-label promotion and use of retatrutide raises questions about medical oversight and patient safety as demand for weight-loss drugs grows.

Key Facts

• Some doctors and nurses are promoting and prescribing retatrutide, which has not been approved by the FDA.
• Zealand Pharma reported that about one-fifth of users discontinued its weight-loss drug during a trial due to gastrointestinal issues.
• Analysts and investors have expressed concerns about the commercial prospects of experimental weight-loss drugs because of side effects.
• Wegovy remains a leading choice among Americans seeking weight loss, even after the introduction of new GLP-1 pills.
• A CBS News investigation found that retatrutide is being offered to patients despite its ongoing clinical trial status.

What Happened

A CBS News investigation found that some healthcare providers are prescribing and promoting retatrutide, a weight-loss drug not yet approved by the FDA, while other experimental drugs in the sector have raised safety and discontinuation concerns.

Why It Matters

The use of unapproved weight-loss drugs highlights regulatory challenges and potential risks for patients, as well as the intense demand for new obesity treatments.

What's Next

Regulatory scrutiny may increase, and further clinical trial results and FDA decisions are expected to shape the future availability and safety monitoring of these drugs.